---
title: "Edding Genor’s Jing Zhu Da Sub-Licensing Deal Collapses After Upstream License Termination"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294992281.md"
description: "Edding Genor's sub-licensing deal for oncology drug Jing Zhu Da collapsed after upstream license termination by Syndax Pharmaceuticals. This halted rights transfer to Suzhou Eddingpharm, which had paid RMB60 million. The board states the impact is immaterial due to diversified operations, but the company is seeking compensation from Taizhou EOC."
datetime: "2026-08-05T15:08:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294992281.md)
  - [en](https://longbridge.com/en/news/294992281.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294992281.md)
generator: "portal-rs"
---

# Edding Genor’s Jing Zhu Da Sub-Licensing Deal Collapses After Upstream License Termination

An announcement from Genor Biopharma Holdings Limited ( (HK:6998) ) is now available.

Edding Genor Group Holdings Limited has disclosed that its 2023 sub-license agreement for the oncology drug Jing Zhu Da in Mainland China can no longer be performed after Syndax Pharmaceuticals terminated an original 2013 license held by EOC Pharma (Hong Kong). The termination means EOC HK has lost rights to the relevant patents and intellectual property, preventing Taizhou EOC from granting Suzhou Eddingpharm the agreed commercialisation rights and halting all related continuing connected transactions.

Suzhou Eddingpharm had already paid RMB60 million in upfront and development milestone fees under the deal and had generated only minimal commission income and royalties, with revenue from Jing Zhu Da staying below 1% of the group’s annual turnover. The board says the cessation will not materially affect operations due to the group’s diversified portfolio, while the company is now in active discussions with Taizhou EOC over compensation for payments made and potential losses, and is reserving its rights and remedies against Taizhou EOC and other parties.

**More about Genor Biopharma Holdings Limited**

Edding Genor Group Holdings Limited, incorporated in the Cayman Islands and listed in Hong Kong, operates in the biopharmaceutical sector through its wholly owned subsidiary Suzhou Eddingpharm. The group focuses on commercialising originator-branded therapies such as Vancocin, Ceclor and FPN, alongside innovative drugs including Vascepa, Mulpleta and Rujianing, targeting diversified treatment areas to reduce reliance on any single product line.

Its market strategy centres on distributing and promoting licensed medicines in Mainland China, leveraging sub-licensing and commercialisation rights for oncology and other specialty products. By maintaining a broad portfolio and focusing on regulatory approval, marketing and post-marketing surveillance, the company seeks stable revenue streams and mitigates the impact of changes in individual licensing arrangements.

**Average Trading Volume:** 1,195,266

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$3.34B

For a thorough assessment of 6998 stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [SNDX.US](https://longbridge.com/en/quote/SNDX.US.md)
- [06998.HK](https://longbridge.com/en/quote/06998.HK.md)

## Related News & Research

- [3D Medicines Fully Enforces Arbitration Win Against SELLAS as Key Trial Nears Endpoint](https://longbridge.com/en/news/296192264.md)
- [SinoMab Seeks Shareholder Approval to Sell Suzhou Industrial Property for RMB280 Million](https://longbridge.com/en/news/296542794.md)
- [TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference](https://longbridge.com/en/news/296174254.md)
- [Diversify Advisory Services LLC Buys New Holdings in Regeneron Pharmaceuticals, Inc. $REGN](https://longbridge.com/en/news/296585791.md)
- [Is Royalty Pharma (RPRX) Undervalued On Its $100 Million Zealand Pharma Royalty Deal?](https://longbridge.com/en/news/296647266.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**